Business
Enzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus)
Enzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus).
About this update from Enzolytics Inc.
[{"type":"text","content":"Production of Monoclonal Antibodies Targeting These Sites Is in Process in the Company's Texas LabCOLLEGE STATION, TX / ACCESSWIRE / February 22, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced it has identified eleven conserved, expectedly immutable sites (epitopes) on the Coronavirus against which it is producing targeted anti-SARS-CoV-2 monoclonal antibodies. Using computer analysis (Artificial Intelligence [AI]), the Company's genetics and molecular biology data science team has now screened more than 50,512 Coronavirus isolates currently known and has identified conserved sites which expectedly are immutable. The 11 conserved sequences identified on the virus isolates curated have been identified on the basis that they are 98.71% to 99.29% conserved over the entirety of the 50,512 Coronavirus isolates analyzed.The Company has filed a comprehensive patent application covering these discoveries. This initial application has been filed in the U.S. and will be extended to claim international patent coverage through the International Patent Cooperation Treaty (PCT) to which 153 countries subscribe. The patent coverage sought includes patent claims on the discovered epitope/antigens, vaccine claims, antibody claims, and related prophylactic/therapeutic method claims relating to the epitope/antigens.Under U.S. and foreign patent laws, filing of a patent application constitutes reduction to practice of the claimed invention. Rights of priority to claimed inventions date from the date of filing of the U.S. application. This priority date will be accorded to the inventions claimed in supplemental U.S. and all foreign corresponding applications filed through the PCT. A PCT filing provides the basis for seeking coverage in any or all of the 153 member countries. The term of protection provided by such patent or patents will be 20 years from the effective filing date. The Company follows a rigorous and comprehensive patent strategy as patent protection is considered a strategic and significant asset of the Company.Before completing the Artificial Intelligence analysis of the 50,512 SARS-CoV-2 isolates to identify conserved epitopes, the Company's scientists predicted a specific target epitope that is correlative in structure to the site on the HIV virus to which the Company h...